Beta Bionics (NASDAQ:BBNX) Research Coverage Started at Bank of America

Bank of America initiated coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report published on Monday, Marketbeat reports. The brokerage issued a buy rating on the stock.

A number of other analysts also recently weighed in on BBNX. LADENBURG THALM/SH SH started coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target on the stock. Robert W. Baird initiated coverage on shares of Beta Bionics in a report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target for the company. Stifel Nicolaus assumed coverage on Beta Bionics in a research note on Monday. They set a “buy” rating and a $25.00 price objective on the stock. Leerink Partners started coverage on Beta Bionics in a research note on Monday. They issued an “outperform” rating and a $28.00 target price for the company. Finally, Baird R W upgraded shares of Beta Bionics to a “hold” rating in a report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Price Performance

BBNX opened at $19.99 on Monday. Beta Bionics has a 52 week low of $18.67 and a 52 week high of $24.50.

Insider Buying and Selling

In other news, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the company’s stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the transaction, the insider now owns 3,901,599 shares of the company’s stock, valued at $66,327,183. The trade was a 34.46 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mike Mensinger acquired 33,350 shares of the stock in a transaction dated Friday, January 31st. The shares were purchased at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the purchase, the insider now directly owns 59,019 shares in the company, valued at $1,003,323. The trade was a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.